Solving Large-Molecule Drug Delivery Challenges
Through Silicon-Based EDS and Next-Generation Soft-Mist Platforms, Enabling Controlled Atomization, Precise Droplet-Size Distribution, and Region-Targeted Deposition
Paris, France | January 21–22, 2026
Suzhou Singmed Medical Device Science and Technology Ltd. (“Singmed”), an inhalation and nasal drug delivery platform company, participated in Pharmapack Europe 2026 in Paris. At the event, Singmed discussed how silicon-based EDS (Exhalation Delivery System) and next-generation soft-mist platforms can be applied to address key challenges in large-molecule drug delivery, particularly the development bottlenecks in terms of controlled aerosol generation, precise droplet-size distribution, and region-targeted deposition.
Throughout Pharmapack 2026, conversations across the industry reflected a shared reality: as pharmaceutical pipelines continue to move toward more complex and large-molecule therapeutics, traditional inhalation and nasal delivery approaches are increasingly difficult to scale and standardize. For many programs, the challenge is no longer molecule discovery, but the absence of delivery platforms that can deliver reproducible aerosol performance and support regulatory-ready development paths.
Singmed approaches this challenge through a platform-based model for inhalation and nasal drug delivery. Unlike traditional device design approaches that focus on individual products, Singmed place its R&D emphasis on the control of core parameters governing aerosol generation and deposition. This allows performance to be repeated, compared, and transferred across formulations and development stages, while reducing variability and overall development risk.
Within this approach, Singmed’s next-generation soft-mist platform is designed to support inhalation delivery of complex therapeutics. Built on proprietary silicon-based atomization engineering, the platform provides controlled atomization and precise droplet-size distribution, helping minimize the variability related to device actuation or formulation differences. In addition, the platform is engineered to minimize exposure to mechanical stress during aerosol generation, thereby mitigate risks associated with loss of molecular integrity in large-molecule delivery. Soft-mist generation is treated as a reusable, platform-level delivery capability, rather than a product-specific feature.
In parallel, Singmed applies silicon-based Soft Mist EDS architecture to nasal delivery applications. By combining soft-mist atomization with EDS positive-pressure delivery, the system enables region-targeted deposition within the nasal cavity and more predictable deposition profiles compared with conventional spray approaches. Through system-level engineering control, this platform provides a scalable and risk-controlled development pathway for advanced nasal drug delivery and potential nose-to-brain therapeutic strategies.
Underpinning the above delivery platforms is Singmed’s Stong fucus on in vitro performance evaluation and regulatory alignment. Singmed applies FDA- and EMA-aligned in-vitro evaluation methodologies to assess aerosol robustness, reproducibility, and consistency over product life. This enables structured comparability and supports bioequivalence-ready development, helping reduce uncertainty as programs progress toward clinical and commercial stages.
Through its participation at Pharmapack Europe 2026, Singmed further reinforced its position as a platform-based partner in inhalation and nasal drug delivery. By combining silicon-based atomization engineering with soft-mist and EDS delivery architectures, Singmed continues to support pharmaceutical and biotechnology partners working in addressing increasing molecular complexity and delivery challenge.
